InvestorsHub Logo


10/22/21 2:20 PM

#9 RE: jondoeuk #8

The company shared initial data from its Material Acquisition Platform, highlighting the ability of its proprietary VELOS manufacturing process to extract personalised cell therapy candidates across several solid tumour types.

Disclosed as part of a presentation at the ESGCT Congress, the data included 74 patient samples that were processed at the time of submission. In line with publicly available data, its PELEUS platform has identified 107 clonal neoantigens in NSCLC samples, 156 in melanoma samples, and 71 in head and neck squamous cell carcinoma samples. The collection of patient material is currently underway across eight sites in the U.K., EU, and the U.S.